Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions
ObesityMenopause
Interventions
DRUG

semaglutide or tirzepatide

Semaglutide and tirzepatide will be dosed as per prescription labels

BEHAVIORAL

Lifestyle modification intervention

All participants will be recommended the following: 1) low-calorie diet based on their predicted by Harris Benedict resting energy expenditure minus 500 kcal per day; 2) physical activity: a goal of 10,000 steps or more per day; 3) exercise: a goal of 150 minutes or more of moderate-intensity aerobic activity (cardiovascular exercise) per week; 4) limited consumption of liquid calories (i.e. sodas, juices, alcohol, etc.).

Trial Locations (1)

32224

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT07057310 - Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women | Biotech Hunter | Biotech Hunter